Welcome to the WCN 2021 Interactive Program
The congress will officially run on Central European Time (CET) - Rome Time
To convert the congress times to your local time Click Here
Please note that all sessions will run at their scheduled time and be followed by a LIVE Q&A/Discussion at the end
The viewing of sessions, cannot be accessed from this conference calendar. All sessions are accessible via the Virtual Platform
- Gioacchino Tedeschi (Italy)
- Massimo Filippi (Italy)
- Claudio Gasperini (Italy)
This session consists of two topics as follow:
• 14:00 - 14:30 - Immune response to SARS-CoV2 infection and vaccination: what have we learnt from patients in treatment with ocrelizumab, chaired by Claudio Gasperini
The recent SARS-COV-2 pandemic has caused a global challenge in the field of MS with a review of the management of current and planned therapies. To date, the literature has allowed us to clarify that, generally, therapies for MS do not seem to increase the risk of contracting COVID-19 or developing a severe form and that there are other predisposing factors such as age, comorbidities, etc. . The world of neurology, however, still has many open questions and needs answers and comparison with the leading experts in immunology to better manage the therapeutic approach towards the available vaccination platforms. The response to vaccination cannot only be based on an assessment of the antibody response but must rather also take into account the cellular response T mediated considering a long-term safety issue.
• 14:30 – 15:30 - Our journey in MS: from current paradigms to future scientific advances, chaired by Massimo Filippi
MS is a chronic disabling disease that requires the patient to undertake a long and complex socio-assistance path. In spite of the wide spectrum of therapeutic opportunities, several MS patients even without clinical or radiological disease activity, despite having a form of relapsing remitting at the beginning, present at some point a worsening linked to a progression that appears to be present from the very first phases of the disease, completely independent from relapse or in any case from the disease activity, even if only radiological. Hence the need for the clinician to adopt clinical, radiological and biohumoral tools (often not yet of routine use) useful for intercepting this delicate phase of the disease in clinical practice. It is important to analyze all the latest scientific evidence in order to promote diagnostic protocols that can be useful in facilitating the recognition and consequently also the management of patients who are in this phase of the disease.
Ocrelizumab: the state of Art from the pandemic challenge to the new Clinical Frontiers
Supported by Roche s.p.a
Introduction
- Claudio Gasperini (Italy)
Immune response to SARS-CoV2 infection and vaccination: what have we learnt from patients in treatment with ocrelizumab?
- Roberto Furlan (Italy)
Q&A
- Claudio Gasperini (Italy)
Our journey in MS: current paradigms
- Diego Centonze (Italy)
Q&A
- Gioacchino Tedeschi (Italy)
- Massimo Filippi (Italy)
Our journey in MS: future scientific advances
- Nicola De Stefano (Italy)
Q&A
- Massimo Filippi (Italy)
- Gioacchino Tedeschi (Italy)